Novartis Ag (NVS) Shares Outstanding (2018 - 2025)
Novartis Ag's (NVS) quarterly Shares Outstanding came in at $1.9 billion in Q4 2025, down 3.39% year-on-year from $2.0 billion in Q4 2024, and down 3.39% quarter-over-quarter from $2.0 billion in Q4 2024.
Novartis Ag (NVS) Shares Outstanding (2018 - 2025) Analysis & Trends
Novartis Ag has disclosed Shares Outstanding across 8 years of filings, most recently posting $1.9 billion for Q4 2025.
- Shares Outstanding for Q4 2025 came in at $1.9 billion, down 3.39% year-over-year; the trailing twelve-month figure through Dec 2025 was $1.9 billion (down 3.39% YoY), and the FY2025 annual result was $1.9 billion, down 3.39% from the prior year.
- Shares Outstanding came in at $1.9 billion for Q4 2025 at Novartis Ag, down from $2.0 billion in the prior quarter.
- In the past five years, Shares Outstanding ranged from a high of $2.2 billion in Q4 2021 to a low of $1.9 billion in Q4 2025.
- The 5-year median for Shares Outstanding is $2.0 billion (2023), against an average of $2.1 billion.
- Across the five-year window, Shares Outstanding fell 0.97% in 2021 and dropped 5.16% in 2022, its largest moves.
- Novartis Ag's Shares Outstanding stood at $2.2 billion in 2021, then declined by 5.16% to $2.1 billion in 2022, then decreased by 3.57% to $2.0 billion in 2023, then dropped by 3.37% to $2.0 billion in 2024, then declined by 3.39% to $1.9 billion in 2025.
- The last three Shares Outstanding figures came in at $1.9 billion (Q4 2025), $2.0 billion (Q4 2024), and $2.0 billion (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 943.50 Mn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 3.12 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | 1.77 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 3.58 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 539.70 Mn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 1.24 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 9.64 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 2.92 Bn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.91 Bn |
| Dec 31, 2025 | 1.91 Bn |
| Dec 31, 2025 | 1.91 Bn |
| Dec 31, 2025 | 1.91 Bn |
| Dec 31, 2025 | 1.91 Bn |
| Dec 31, 2025 | 1.91 Bn |
| Dec 31, 2025 | 1.91 Bn |
| Dec 31, 2025 | 1.91 Bn |
| Dec 31, 2024 | 1.98 Bn |
| Dec 31, 2024 | 1.98 Bn |
| Dec 31, 2024 | 1.98 Bn |
| Dec 31, 2024 | 1.98 Bn |
| Dec 31, 2024 | 1.98 Bn |
| Dec 31, 2024 | 1.98 Bn |
| Dec 31, 2024 | 1.98 Bn |
| Dec 31, 2024 | 1.98 Bn |
| Dec 31, 2023 | 2.04 Bn |
| Dec 31, 2023 | 2.04 Bn |
| Dec 31, 2023 | 2.04 Bn |
| Dec 31, 2023 | 2.04 Bn |